Published in Arthritis Rheum on July 01, 2002
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis (2011) 1.96
Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis (2008) 1.51
Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther (2004) 1.25
Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther (2011) 1.21
Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int (2011) 1.17
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther (2007) 1.13
Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int (2005) 1.11
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther (2009) 1.02
Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis (2007) 1.00
Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol (2004) 1.00
Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res Ther (2004) 0.99
Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Res Ther (2015) 0.90
Therapeutic implications of osteoprotegerin. Cancer Cell Int (2009) 0.89
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int (2006) 0.89
Secondary osteoporosis in patients with juvenile idiopathic arthritis. J Osteoporos (2011) 0.88
Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis (2007) 0.88
Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol (2007) 0.86
Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis Res Ther (2012) 0.84
Biomarkers predicting a need for intensive treatment in patients with early arthritis. Curr Pharm Des (2015) 0.83
Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major. J Bone Miner Metab (2007) 0.82
Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol (2007) 0.81
The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis. Rheumatol Int (2007) 0.81
Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. Clin Rheumatol (2008) 0.81
Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. Arthritis Res Ther (2014) 0.80
Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy. Biologics (2008) 0.80
Dickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosus. J Clin Immunol (2010) 0.79
Bone and TNF in rheumatoid arthritis: clinical implications. RMD Open (2015) 0.79
Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int (2016) 0.79
Cyclic adenosine 5'-monophosphate in synovial fluid of rheumatoid arthritis and osteoarthritis patients. Rheumatol Int (2008) 0.78
Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report. BMC Gastroenterol (2014) 0.78
sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis. Rheumatol Int (2008) 0.78
Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci (2012) 0.78
Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Arthritis Res Ther (2011) 0.78
Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. Sci Rep (2016) 0.77
A model to explain specific cellular communications and cellular harmony:- a hypothesis of coupled cells and interactive coupling molecules. Theor Biol Med Model (2014) 0.76
Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS One (2016) 0.75
A proteomic profile of synoviocyte lesions microdissected from formalin-fixed paraffin-embedded synovial tissues of rheumatoid arthritis. Clin Proteomics (2015) 0.75
Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis. Biomed Res Int (2017) 0.75
A variant in the osteoprotegerin gene is associated with coronary atherosclerosis in patients with rheumatoid arthritis: results from a candidate gene study. Int J Mol Sci (2015) 0.75
Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis. Dis Markers (2015) 0.75
Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk. Heart Vessels (2017) 0.75
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Photo-leucine and photo-methionine allow identification of protein-protein interactions in living cells. Nat Methods (2005) 2.24
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis (2011) 2.13
Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis (2010) 1.78
Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group. Arthritis Res Ther (2012) 1.44
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol (2010) 1.44
Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol (2004) 1.33
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis (2012) 1.31
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis (2010) 1.31
Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther (2004) 1.25
The mammalian oxysterol-binding protein-related proteins (ORPs) bind 25-hydroxycholesterol in an evolutionarily conserved pocket. Biochem J (2007) 1.20
Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum (2004) 1.17
Elevated number of recently activated T cells in bone marrow of patients with rheumatoid arthritis: a role for interleukin 15? Ann Rheum Dis (2010) 1.10
Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res (2004) 1.09
Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Ann Rheum Dis (2011) 1.06
Still's disease in patient with silicone breast implants: case report. Pol Arch Med Wewn (2008) 1.06
Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit (2011) 1.01
Functional TLR9 modulates bone marrow B cells from rheumatoid arthritis patients. Eur J Immunol (2009) 1.00
Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ (2014) 0.99
The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. J Mol Med (Berl) (2012) 0.93
Perna canaliculus lipid complex PCSO-524™ demonstrated pain relief for osteoarthritis patients benchmarked against fish oil, a randomized trial, without placebo control. Mar Drugs (2013) 0.92
Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol (2003) 0.90
Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid (2007) 0.87
Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis. Pol Arch Med Wewn (2015) 0.87
Does the KIR2DS5 gene protect from some human diseases? PLoS One (2010) 0.86
IL-17A, IL-17F and IL-23R Gene Polymorphisms in Polish Patients with Rheumatoid Arthritis. Arch Immunol Ther Exp (Warsz) (2014) 0.84
CD8(+) T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein. Transplantation (2006) 0.84
Rapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumab. Joint Bone Spine (2009) 0.83
Peripheral blood Th17/Treg imbalance in patients with low-active systemic lupus erythematosus. Postepy Hig Med Dosw (Online) (2014) 0.81
Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int (2010) 0.81
Allograft inflammatory factor-1 gene polymorphisms in patients with rheumatoid arthritis. Genet Test Mol Biomarkers (2011) 0.80
The presumed hyporesponsive behavior of rheumatoid arthritis T lymphocytes can be attributed to spontaneous ex vivo apoptosis rather than defects in T cell receptor signaling. J Immunol (2009) 0.80
[A case of early recognized Wegener's granulomatosis with renal involvement. Insights for early diagnosis]. Ann Acad Med Stetin (2010) 0.80
[The role of Th1, Th17, and Treg cells in the pathogenesis of rheumatoid arthritis including anti-inflammatory action of Th1 cytokines]. Postepy Hig Med Dosw (Online) (2011) 0.79
Selective inhibition of cyclooxygenase 2-generated prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by taurine chloramine. Arthritis Rheum (2003) 0.79
Occupational work and quality of life in osteoarthritis patients. Rheumatol Int (2006) 0.79
The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheumatol (2004) 0.79
Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. Med Sci Monit (2011) 0.79
Prevalence of thyroid diseases and antithyroid antibodies in women with rheumatoid arthritis. Pol Arch Med Wewn (2009) 0.79
Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. Arthritis Rheum (2009) 0.79
Alterations in both the activatory and inhibitory potential of peripheral blood CD4+ T cells in rheumatoid arthritis patients correlate with disease progression. Pathol Oncol Res (2013) 0.78
Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement. Rheumatol Int (2013) 0.78
Measurement of the inflammatory response in the early postoperative period after hip and knee arthroplasty. Clin Chem Lab Med (2015) 0.77
Work ability in ageing workers suffering from chronic diseases. Int J Occup Saf Ergon (2006) 0.77
[Active psoriatic arthritis during pregnancy: challenges and limitations of pharmacotherapy]. Ann Acad Med Stetin (2010) 0.77
Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus. Adv Clin Exp Med (2012) 0.77
[The role of Salmonella and Yersinia in the pathogenesis of spondyloarthropathies and rheumatoid arthritis. I. Detection of bacteria, bacterial DNA, lipopolysaccharide and ECA antigen in synovial fluid or blood]. Med Dosw Mikrobiol (2005) 0.76
Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation. Rheumatol Int (2013) 0.75
Inclusion body myositis associated with Sjögren's syndrome. Rheumatol Int (2012) 0.75
[Follow-up studies of rheumatoid arthritis patients with the presence of antiphospholipid antibodies]. Pol Arch Med Wewn (2006) 0.75
[Eosinophilic fasciitis--a case report]. Wiad Lek (2012) 0.75
[Total hip arthroplasty after previous support proximal femoral osteotomy]. Chir Narzadow Ruchu Ortop Pol (2010) 0.75
[Polymyalgia rheumatica mimicking neoplastic disease--significant problem in elderly patients]. Pol Arch Med Wewn (2008) 0.75
[Role of Salmonella and Yersinia in the pathogenesis of spondyloarthropathies and rheumatoid arthritis. II. Antibodies to Salmonella and Yersinia in sera and synovial fluids]. Med Dosw Mikrobiol (2005) 0.75
[Preliminary data concerning cross-reacting anticardiolipin antibodies as potential inhibiting endotoxin activity factors]. Pol Arch Med Wewn (2006) 0.75
[Coexistence of systemic sclerosis and gout? Hyperuricemia in systemic sclerosis: case report and literature review]. Ann Acad Med Stetin (2012) 0.75
[Bilateral exophthalmos requiring rheumatologic consultation. A case of the Churg-Strauss syndrome]. Ann Acad Med Stetin (2012) 0.75
[Modular short-stem prosthesis in total hip arthroplasty--preliminary report]. Chir Narzadow Ruchu Ortop Pol (2008) 0.75
[Treatment outcome of spondyloarthropathy with infliximab]. Pol Arch Med Wewn (2005) 0.75
[Nodular changes in lungs in a patient with rheumatoid arthritis. Diagnostic and therapeutic difficulties. Case report]. Ann Acad Med Stetin (2010) 0.75
[Influence of genetic factors on development and severity of rheumatoid arthritis--part I]. Pol Merkur Lekarski (2009) 0.75
Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. Rheumatology (Oxford) (2013) 0.75
[Toxic epidermal necrolysis during therapy with sulphasalazine in a patient with arthritis. Case report]. Wiad Lek (2011) 0.75
[Application of porous composite hydroxyapatite-TCP implants in orthopaedic surgery]. Chir Narzadow Ruchu Ortop Pol (2008) 0.75
[Enhanced ocular staining score in patients with primary Sjögren's syndrome]. Klin Oczna (2014) 0.75
Reactive arthritis. Pol Arch Med Wewn (2009) 0.75
[Inhibition of cardiolipin binding antibodies from synovial fluids of patients with arthritis by endotoxin]. Pol Arch Med Wewn (2006) 0.75